254 related articles for article (PubMed ID: 33313798)
1. Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Juul Kildemoes R; Højby Rasmussen M; Agersø H; Overgaard RV
J Clin Endocrinol Metab; 2021 Jan; 106(2):567-576. PubMed ID: 33313798
[TBL] [Abstract][Full Text] [Related]
2. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Horikawa R; Juul RV; Saenger P;
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1847-61. PubMed ID: 31917835
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials.
Juul RV; Rasmussen MH; Agersø H; Overgaard RV
Clin Pharmacokinet; 2019 Jan; 58(1):63-75. PubMed ID: 29671202
[TBL] [Abstract][Full Text] [Related]
4. Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency.
Kildemoes RJ; Hollensen C; Biller BMK; Johannsson G; Takahashi Y; Rasmussen MH
Eur J Endocrinol; 2022 May; 187(1):27-38. PubMed ID: 35521713
[TBL] [Abstract][Full Text] [Related]
5. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
[TBL] [Abstract][Full Text] [Related]
6. Model-Based Analysis of IGF-I Response, Dosing, and Monitoring for Once-Weekly Somapacitan in Children With GH Deficiency.
Kildemoes RJ; Backeljauw PF; Højby M; Blair JC; Miller BS; Mori J; Lyauk YK
J Endocr Soc; 2023 Oct; 7(11):bvad115. PubMed ID: 37818403
[TBL] [Abstract][Full Text] [Related]
7. Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial.
Mori J; Ohata Y; Fujisawa Y; Sato Y; Röhrich S; Rasmussen MH; Bang RB; Horikawa R
Clin Endocrinol (Oxf); 2024 Apr; 100(4):389-398. PubMed ID: 38368603
[TBL] [Abstract][Full Text] [Related]
8. Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3.
Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Saenger P; Horikawa R
J Clin Endocrinol Metab; 2022 Apr; 107(5):1357-1367. PubMed ID: 34964458
[TBL] [Abstract][Full Text] [Related]
9. Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial.
Johannsson G; Gordon MB; Højby Rasmussen M; Håkonsson IH; Karges W; Sværke C; Tahara S; Takano K; Biller BMK
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1358-76. PubMed ID: 32022863
[TBL] [Abstract][Full Text] [Related]
10. Absorption, metabolism and excretion of once-weekly somapacitan, a long-acting growth hormone derivative, after single subcutaneous dosing in human subjects.
Helleberg H; Bjelke M; Damholt BB; Pedersen PJ; Rasmussen MH
Eur J Pharm Sci; 2021 Dec; 167():106030. PubMed ID: 34601071
[TBL] [Abstract][Full Text] [Related]
11. Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.
Garner T; Clayton P; Højby M; Murray P; Stevens A
J Clin Endocrinol Metab; 2024 Apr; 109(5):1214-1221. PubMed ID: 38066644
[TBL] [Abstract][Full Text] [Related]
12. Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH.
Miller BS; Blair JC; Rasmussen MH; Maniatis A; Mori J; Böttcher V; Kim HS; Bang RB; Polak M; Horikawa R
J Clin Endocrinol Metab; 2023 Nov; 108(12):3090-3099. PubMed ID: 37406251
[TBL] [Abstract][Full Text] [Related]
13. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.
Thygesen P; Andersen HS; Behrens C; Fels JJ; Nørskov-Lauritsen L; Rischel C; Johansen NL
Growth Horm IGF Res; 2017 Aug; 35():8-16. PubMed ID: 28595133
[TBL] [Abstract][Full Text] [Related]
14. Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials.
Bentz Damholt B; Dombernowsky SL; Dahl Bendtsen M; Bisgaard C; Højby Rasmussen M
Clin Pharmacokinet; 2021 Aug; 60(8):1015-1027. PubMed ID: 33754315
[TBL] [Abstract][Full Text] [Related]
15. Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial.
Miller BS; Blair JC; Rasmussen MH; Maniatis A; Kildemoes RJ; Mori J; Polak M; Bang RB; Böttcher V; Stagi S; Horikawa R
J Clin Endocrinol Metab; 2022 Nov; 107(12):3378-3388. PubMed ID: 36062966
[TBL] [Abstract][Full Text] [Related]
16. Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3.
Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Röhrich S; Saenger P; Horikawa R
J Clin Endocrinol Metab; 2023 Sep; 108(10):2569-2578. PubMed ID: 36995872
[TBL] [Abstract][Full Text] [Related]
17. Similar safety and efficacy in previously treated adults with growth hormone deficiency randomized to once-weekly somapacitan or daily growth hormone.
Otsuka F; Takahashi Y; Tahara S; Ogawa Y; Højby Rasmussen M; Takano K
Clin Endocrinol (Oxf); 2020 Nov; 93(5):620-628. PubMed ID: 32603494
[TBL] [Abstract][Full Text] [Related]
18. Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan.
Miller BS; Blair J; Horikawa R; Linglart A; Yuen KCJ
Drug Des Devel Ther; 2024; 18():291-306. PubMed ID: 38333899
[TBL] [Abstract][Full Text] [Related]
19. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial.
Johannsson G; Feldt-Rasmussen U; Håkonsson IH; Biering H; Rodien P; Tahara S; Toogood A; Rasmussen MH;
Eur J Endocrinol; 2018 May; 178(5):491-499. PubMed ID: 29500310
[TBL] [Abstract][Full Text] [Related]
20. Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study.
Cohen P; Rogol AD; Howard CP; Bright GM; Kappelgaard AM; Rosenfeld RG;
J Clin Endocrinol Metab; 2007 Jul; 92(7):2480-6. PubMed ID: 17356043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
